RU2006129469A - 2, 4-DIAMINOPYRIMIDINES AND THEIR APPLICATION FOR THE INDUCTION OF CARDIOMYOGENESIS - Google Patents
2, 4-DIAMINOPYRIMIDINES AND THEIR APPLICATION FOR THE INDUCTION OF CARDIOMYOGENESIS Download PDFInfo
- Publication number
- RU2006129469A RU2006129469A RU2006129469/04A RU2006129469A RU2006129469A RU 2006129469 A RU2006129469 A RU 2006129469A RU 2006129469/04 A RU2006129469/04 A RU 2006129469/04A RU 2006129469 A RU2006129469 A RU 2006129469A RU 2006129469 A RU2006129469 A RU 2006129469A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- compound
- mammalian cell
- group
- member selected
- Prior art date
Links
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 25
- 210000004027 cell Anatomy 0.000 claims 22
- 210000004962 mammalian cell Anatomy 0.000 claims 19
- 241000124008 Mammalia Species 0.000 claims 9
- 230000002107 myocardial effect Effects 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims 6
- 230000004069 differentiation Effects 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 210000004165 myocardium Anatomy 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 201000009030 Carcinoma Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 210000004413 cardiac myocyte Anatomy 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 210000005003 heart tissue Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 claims 1
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 claims 1
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 claims 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 claims 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 claims 1
- 101150114527 Nkx2-5 gene Proteins 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 101150014102 mef-2 gene Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002235 sarcomere Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Claims (51)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53714404P | 2004-01-16 | 2004-01-16 | |
US60/537,144 | 2004-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006129469A true RU2006129469A (en) | 2008-02-27 |
Family
ID=34794442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006129469/04A RU2006129469A (en) | 2004-01-16 | 2005-01-14 | 2, 4-DIAMINOPYRIMIDINES AND THEIR APPLICATION FOR THE INDUCTION OF CARDIOMYOGENESIS |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050209231A1 (en) |
EP (1) | EP1727806A1 (en) |
JP (1) | JP2007517831A (en) |
KR (1) | KR20060133552A (en) |
CN (1) | CN1910159A (en) |
AU (1) | AU2005205167A1 (en) |
BR (1) | BRPI0506839A (en) |
CA (1) | CA2551770A1 (en) |
RU (1) | RU2006129469A (en) |
WO (1) | WO2005068437A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2626234T3 (en) | 2004-07-30 | 2017-07-24 | Mayo Foundation For Medical Education And Research | Cardiovascular tissue treatment |
CA2655315A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
CN101506175A (en) * | 2006-06-15 | 2009-08-12 | 贝林格尔·英格海姆国际有限公司 | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha |
US9765298B2 (en) | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
KR100937457B1 (en) * | 2007-08-10 | 2010-01-19 | 한국생명공학연구원 | A Method for differentiating of human embryonic stem cells and human embryonic carcinoma cells into the cardiomyocytic lineages |
CN107050057B (en) * | 2007-09-19 | 2021-04-20 | 普拉里斯坦有限公司 | Adherent cells from adipose or placental tissue and their use in therapy |
WO2009145761A1 (en) | 2008-05-27 | 2009-12-03 | Mayo Foundation For Medical Education And Research | Methods and materials for using cells to treat heart tissue |
US9719146B2 (en) | 2009-09-09 | 2017-08-01 | General Electric Company | Composition and method for imaging stem cells |
AT509266B1 (en) * | 2009-12-28 | 2014-07-15 | Tech Universität Wien | SUBSTITUTED PYRIDINES AND PYRIMIDINES |
CA2786999A1 (en) * | 2010-01-13 | 2011-07-21 | Glaxosmithkline Llc | Compounds and methods |
US9695137B2 (en) * | 2013-03-14 | 2017-07-04 | The University Of Toledo | Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same |
WO2018055235A1 (en) * | 2016-09-21 | 2018-03-29 | University Of Helsinki | Isoxazole-amides for treating cardiac diseases |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
PE20221010A1 (en) | 2019-08-14 | 2022-06-15 | Incyte Corp | IMIDAZOLIL PYRIMIDINILAMINE COMPOUNDS AS CDK2 INHIBITORS |
JP2022551668A (en) | 2019-10-11 | 2022-12-12 | インサイト・コーポレイション | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127996C (en) * | 1963-11-19 | |||
ES2253266T3 (en) * | 1999-11-30 | 2006-06-01 | Pfizer Products Inc. | 2,4-DIAMINOPIRIMIDINE COMPOUNDS USED AS IMMUNOSUPPRESSORS. |
HUP0301117A3 (en) * | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
US6630469B2 (en) * | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
US6958340B2 (en) * | 2001-08-01 | 2005-10-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2005512972A (en) * | 2001-10-12 | 2005-05-12 | アイアールエム エルエルシー | Kinase inhibitor scaffolds and methods for their preparation |
AU2002363176B2 (en) * | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors) |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
-
2005
- 2005-01-14 AU AU2005205167A patent/AU2005205167A1/en not_active Abandoned
- 2005-01-14 WO PCT/EP2005/000323 patent/WO2005068437A1/en active Application Filing
- 2005-01-14 CA CA002551770A patent/CA2551770A1/en not_active Abandoned
- 2005-01-14 BR BRPI0506839-8A patent/BRPI0506839A/en not_active IP Right Cessation
- 2005-01-14 JP JP2006548273A patent/JP2007517831A/en active Pending
- 2005-01-14 RU RU2006129469/04A patent/RU2006129469A/en not_active Application Discontinuation
- 2005-01-14 KR KR1020067014159A patent/KR20060133552A/en not_active Application Discontinuation
- 2005-01-14 EP EP05700922A patent/EP1727806A1/en not_active Withdrawn
- 2005-01-14 US US11/035,708 patent/US20050209231A1/en not_active Abandoned
- 2005-01-14 CN CNA200580002024XA patent/CN1910159A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20060133552A (en) | 2006-12-26 |
AU2005205167A1 (en) | 2005-07-28 |
US20050209231A1 (en) | 2005-09-22 |
JP2007517831A (en) | 2007-07-05 |
WO2005068437A1 (en) | 2005-07-28 |
CA2551770A1 (en) | 2005-07-28 |
BRPI0506839A (en) | 2007-06-12 |
CN1910159A (en) | 2007-02-07 |
EP1727806A1 (en) | 2006-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006129469A (en) | 2, 4-DIAMINOPYRIMIDINES AND THEIR APPLICATION FOR THE INDUCTION OF CARDIOMYOGENESIS | |
RU2647467C2 (en) | New method of treatment of myocardial infarction with application of fragment hmgb1 | |
JP2013040209A (en) | Tlr agonist | |
US20210401993A1 (en) | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells | |
WO2002019893A2 (en) | Improved cardiac function through administration of es cells | |
US20220127226A1 (en) | Anti-arrhythmicity agents | |
RU2649069C2 (en) | Novel method for treating spinal cord injury using hmgb1 fragment | |
RU2007138582A (en) | ORAL DOSAGE FORMS OF HEMCITABINE DERIVATIVES | |
AU2018213671A1 (en) | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure | |
CA2458318A1 (en) | Wortmannin analogs and methods of using same | |
WO2010141946A1 (en) | Peptide-coated cell localization to diseased or damaged tissues and methods related thereto | |
JP2004504807A (en) | Multipotent cells and cardiomyocyte populations, and routes to the populations and uses thereof | |
JP6469009B2 (en) | Beta-hydroxylase inhibitors for cancer treatment | |
US20220218715A1 (en) | Novel use of pyrrolo-pyridine derivative compound for prevention and/or treatment of cancer | |
Labarthe et al. | Cutaneous manifestations of relapsing polychondritis in a patient receiving goserelin for carcinoma of the prostate | |
JP7113007B2 (en) | Peptides and their use for inducing tissue regeneration | |
KR100903974B1 (en) | Novel 2,4,5-trisubtituted-1,3-thiazole derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for antiinflammatory disease induced by spc activity containing 2,4,5-trisubstituted-1,3-thiazole derivatives as an effective ingredient | |
WO2012036383A2 (en) | Use of a protein tyrosine kinase inhibitor for inducing the differentiation of mesenchymal stem cells into cardiogenic cells | |
JP2018095629A (en) | Novel compound, and cardiomyocyte proliferation inducer containing the same as active ingredient, and therapeutic agent for disease associated with myocardial dysfunction | |
US11162077B2 (en) | Apicidin-containing composition for inducing differentiation of mesenchymal stem cells into cardiac-committed cells | |
KR101051078B1 (en) | 2,4-disubstituted-5-aminocarbonyl-1,3-thiazole derivatives for the treatment of inflammation-related diseases, methods for their preparation and agents for the treatment of inflammation-related diseases caused by SPC receptor activity containing them as active ingredients | |
CN114591265A (en) | Benzothiazole compound, pharmaceutical composition, preparation method and application thereof | |
JP2006180763A (en) | Tissue stem cell growing agent | |
JP2020019718A (en) | Cardiac muscle differentiation promoter and cardiac muscle differentiation promoting method | |
JP5437331B2 (en) | Pharmaceutical composition and method for improving cardiac function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20080304 |